Breaking News Instant updates and real-time market news.

ABT

Abbott

$83.11

-0.69 (-0.82%)

07:38
07/17/19
07/17
07:38
07/17/19
07:38

Abbott CEO says 'Our sales growth accelerated and is sustainable'

"Our sales growth accelerated and is sustainable," said Miles D. White, chairman and CEO, Abbott. "We have great momentum and are raising our guidance above the strong outlook we previously set for the year."

  • 17

    Jul

ABT Abbott
$83.11

-0.69 (-0.82%)

04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".
04/18/19
LSCM
04/18/19
NO CHANGE
Target $100
LSCM
Buy
Investors should buy into Tandem Diabetes 'fire sale,' says Lake Street
Lake Street analyst Brooks O'Neil attributes the recent selloff in shares of Tandem Diabetes (TNDM) to investor fears related to the potential implications of "Medicare For All." Yesterday, the decline also appeared to "draw fuel from the strong growth" Abbott (ABT) reported for its Libre glucose monitor for diabetics, O'Neil tells investors in a research note titled "Fire Sale. Should You Buy? Yes. There Is No Fire. Affirm BUY, $100 PT." The analyst doubts the healthcare system will be changed significantly and on Libre, he says, "We're sorry, but we believe investors are either badly confused or just plain wrong." Abbott offers a low-cost version of the monitoring system but does not compete in any way with Tandem in its pump market, says the analyst. Rather, O'Neil thinks there are "potentially significant positives" for Tandem Diabetes related to the "enormous success" of Abbott's Libre franchise. The analyst sees an "extraordinarily positive" outlook for Tandem Diabetes and recommends buying the shares on the recent pullback. He affirms a Buy rating on the shares with a $100 price target.
04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.

TODAY'S FREE FLY STORIES

ARDX

Ardelyx

$4.34

-0.05 (-1.14%)

06:55
10/17/19
10/17
06:55
10/17/19
06:55
Conference/Events
Ardelyx to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:54
10/17/19
10/17
06:54
10/17/19
06:54
Earnings
PPG sees FY19 adjusted EPS $6.17-$6.27, consensus $6.24 »

"As we look ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SAM

Boston Beer

06:53
10/17/19
10/17
06:53
10/17/19
06:53
Upgrade
Boston Beer rating change  »

Cowen upgrades Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:52
10/17/19
10/17
06:52
10/17/19
06:52
Earnings
PPG reports Q3 adjusted EPS $1.67, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
KeyCorp sees long-term ROTCE 16%-19% »

Long-term targets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AUMN

Golden Minerals

$0.22

0.0042 (1.91%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
Golden Minerals enters option agreement to sell Santa Maria Project »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLO

Allogene Therapeutics

$26.36

0.41 (1.58%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Conference/Events
Allogene Therapeutics management to meet with BTIG »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
KeyCorp sees Q4 net interest income 'relatively stable' »

In slides being presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

DOV

Dover

$95.71

-0.24 (-0.25%)

06:50
10/17/19
10/17
06:50
10/17/19
06:50
Earnings
Dover tightens FY19 adj. EPS view to $5.82-$5.85 from $5.75-$5.85 

Consensus $5.82.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

SON

Sonoco

$58.27

0.75 (1.30%)

06:49
10/17/19
10/17
06:49
10/17/19
06:49
Earnings
Sonoco narrows FY19 base EPS view to $3.50-$3.54 from $3.52-$3.62 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

DOV

Dover

$95.71

-0.24 (-0.25%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Dover reports Q3 adj. EPS $1.60, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

ARQL

ArQule

$8.97

0.32 (3.70%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Initiation
ArQule initiated  »

ArQule initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Breaking Earnings news story on Sonoco »

Sonoco sees Q4 base EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:47
10/17/19
10/17
06:47
10/17/19
06:47
Earnings
Sonoco reports Q3 base EPS 97c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BWXT

BWX Technologies

$56.09

-0.33 (-0.58%)

06:46
10/17/19
10/17
06:46
10/17/19
06:46
Hot Stocks
BWX Technologies awarded $806M contract from U.S. Navy »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Recommendations
Netflix analyst commentary  »

SunTrust incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AAPL

Apple

$234.59

-0.67 (-0.28%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Periodicals
EU examining Apple Pay for antitrust concerns, FT reports »

Apple's Apple Pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ALV

Autoliv

$80.64

0.93 (1.17%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Upgrade
Autoliv rating change  »

Autoliv upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$255.02

-19.58 (-7.13%)

06:44
10/17/19
10/17
06:44
10/17/19
06:44
Recommendations
ServiceNow analyst commentary  »

ServiceNow selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:43
10/17/19
10/17
06:43
10/17/19
06:43
Periodicals
We Company forms committee to consider financing lifeline, Reuters reports »

The We Company (WE) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$119.70

-0.25 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 14

    Jan

CDXC

ChromaDex

$3.41

0.41 (13.67%)

06:41
10/17/19
10/17
06:41
10/17/19
06:41
Hot Stocks
ChromaDex reports new study on nicotinamide riboside importance »

ChromaDex announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$55.47

0.46 (0.84%)

06:39
10/17/19
10/17
06:39
10/17/19
06:39
Downgrade
Brunswick rating change  »

Longbow downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MTB

M&T Bank

$159.14

0.27 (0.17%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Earnings
M&T Bank reports Q3 EPS $3.47, consensus $3.57 »

Reports Q3 common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NEPT

Neptune Wellness

$3.49

0.03 (0.87%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Neptune Wellness to provide extraction services to farming services operation »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSRGY

Nestle

$0.00

(0.00%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Nestle says portfolio management 'fully on track' »

Nestle notes that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.